For this second half of 2023, Bioeconomy Corporation will be relaunching an enhanced version of the Biotechnology Commercialisation Fund (BCF) with more attractive borrowing package in terms of pricing, principal grace period and repayment tenure.
Additionally, the utilisation of financing proceeds have been relaxed to accommodate a wider purpose of applicable debt financing requirements. These include viable initial commercialisation initiatives, working capital financing for existing operations, as well as capital expansion requirements, ranging from the purchase of used machineries to acquisition of business properties.
Both funding programmes are non-mutually exclusive and shall be available for both locally-controlled companies as well as foreign-controlled companies.
Send your questions by filling up the form below.